Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.61 |
| ▸ | CDK4 | P11802 | 6/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974684 | 0.90 | CDK2 (0.66) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL7988076 | 0.89 | CDK2 (0.61) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL699562 | 0.87 | CDK2 (0.73) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL699927 | 0.87 | HDAC1 (0.72) | CDK2CDK4CCNE1HDAC1 | |
| SCHEMBL699928 | 0.87 | CDK2 (0.61) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL700084 | 0.83 | XIAP (0.45) | CDK2CDK4CCNE1HDAC1 | |
| SCHEMBL700587 | 0.83 | CDK2 (0.69) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL699844 | 0.83 | HDAC1 (0.59) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL700082 | 0.81 | CDK2 (0.59) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL699642 | 0.81 | CDK2 (0.61) | CDK2CDK4CCNE1HDAC1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.